Valuation: Verastem, Inc.

Market Cap 39Cr 34Cr 32Cr 29Cr 56Cr 3.74TCr 56Cr 378.44Cr 147.28Cr 1.84TCr 147.18Cr 143.95Cr 6.36TCr P/E 2026 *
-2.82x
P/E 2027 * -3.99x
Enterprise Value 23Cr 20Cr 18Cr 17Cr 32Cr 2.16TCr 33Cr 219.11Cr 85Cr 1.06TCr 85Cr 83Cr 3.68TCr EV / Sales 2026 *
2.22x
EV / Sales 2027 * 1.02x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-0.89%
1 week+16.75%
Current month+16.75%
1 month+20.22%
3 months-18.61%
6 months-35.17%
Current year-42.23%
1 week 3.84
Extreme 3.835
4.74
1 month 3.43
Extreme 3.43
4.74
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
45.78
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06Sell

Chief Financial Officer

-4,089 0.0066%
22/06Sell

Chief Executive Officer

-20,871 0.0339%
21/05Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%+16.75%-7.08%-43.97% 39Cr
-2.14%+3.51%+74.05%+131.10% 5.77TCr
-0.93%-2.54%+73.64%+93.71% 5.47TCr
-3.71%-0.35%-14.61%-11.19% 2.38TCr
-0.05%+6.49%+14.05%+451.36% 2.42TCr
-2.96%+6.36%+46.91%-2.65% 1.98TCr
-2.19%+6.34%+40.74%-29.60% 1.71TCr
+3.58%+13.78%+196.41%+348.55% 1.68TCr
-2.48%+17.26%+45.15% - 1.56TCr
-0.57%+2.30%+20.33%+187.27% 1.4TCr
Average -1.18%+6.90%+48.96%+124.95% 2.44TCr
Weighted average by Cap. -1.38%+4.17%+58.19%+136.67%

Financials

2026 *2027 *
Net sales 10Cr 8.96Cr 8.25Cr 7.66Cr 15Cr 975.74Cr 15Cr 99Cr 38Cr 478.95Cr 38Cr 38Cr 1.66TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.71TCr 26Cr 172.63Cr 67Cr 837.09Cr 67Cr 66Cr 2.9TCr
Net income -17Cr -15Cr -13Cr -12Cr -24Cr -1.59TCr -24Cr -160.49Cr -62Cr -778.2Cr -62Cr -61Cr -2.7TCr -14Cr -12Cr -11Cr -11Cr -20Cr -1.35TCr -20Cr -136.71Cr -53Cr -662.91Cr -53Cr -52Cr -2.3TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -24Cr -159.32Cr -62Cr -772.56Cr -62Cr -61Cr -2.68TCr -21Cr -18Cr -17Cr -16Cr -30Cr -2TCr -30Cr -202.39Cr -79Cr -981.39Cr -79Cr -77Cr -3.4TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
06/26/06 $4.460 -0.89% 18,11,512
02/26/02 $4.500 +9.76% 29,67,738
01/26/01 $4.100 +7.33% 21,86,504
30/26/30 $3.820 0.00% 34,45,491
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.460USD
Average target price
15.12USD
Spread / Average Target
+239.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock